Virus-Driven Immunotherapies for Cancer

DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an aggressive form of brain cancer. The company’s pipeline includes viruses armed with potent immunomodulatory molecules to treat cancer. learn more >

Technology IconTechnology

DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses that maximize safety and efficacy.
learn more >

Pipeline IconPipeline

A pipeline of novel viral-driven immunotherapies is being developed for the treatment of a variety of aggressive cancers.
learn more >

Clinical Trials IconFor Patients

Human clinical trials of DNAtrix therapies are ongoing for patients diagnosed with glioblastoma, an aggressive form of brain cancer.
learn more >